Elgan Pharma and Isotopia Molecular Imaging Signed on a Strategic agreement for Phase III and commercial Contract Manufacturing Services

Latest news from Isotopia Ltd Latest news from Isotopia Ltd Petach Tikva, Israel – May 6st 2021 Isotopia Molecular Imaging Limited (Isotopia) and Elgan Pharma Limited (Elgan), have entered into a long-term agreement for development and manufacturing of clinical batches of lyophilized product. “The combination of Isotopia’s capabilities in sterile production, with high level of cGMP …

Israeli researchers developing radioactive marker to detect small, aggressive cancerous tumors

Marker will determine type of tumor in a single image, eliminating the need for a biopsy Today, more than 200,000 cancer patients and persons in remission live in Israel. Every year, nearly 28,000 new cancer patients are diagnosed in Israel, approximately 400 of which are children. According to data from the National Cancer Registry at …

Jubilant Radiopharma and Isotopia Molecular Imaging Enter into a Strategic Partnership to Further Advance the Field of Radiotherapeutics

Jubilant Radiopharma and Isotopia Molecular Imaging Enter into a Strategic Partnership to Further Advance the Field of Radiotherapeutics Our latest news Our latest news Yardley, PA and Petach Tikva, Israel – March 16, 2021. Isotopia Molecular Imaging Limited (Isotopia) and Jubilant Radiopharma, a business division of Jubilant Pharma Limited, have entered into a strategic commercial …

Isotopia and M.T.T.I signed for the supply of Lu-177 n.c.a

Isotopia and M.T.T.I signed for the supply of Lu-177 n.c.a Isotopia Molecular Imaging and Molecular Targeting Technologies (M.T.T.I) havesigned a clinical supply agreement for Lu177 n.c.a. Isotopia Ltd is pleased to announcethat it has begun a collaboration with Molecular Targeting Technologies, Inc. (MTTI), a clinical stage biopharmaceutical company, for the supply of the medical radioisotopeno-carrier-added 177Lu …

ARTMS and Isotopia Molecular Imaging Announce successful Multi-Curie Labeling of PSMA-11

ARTMS and Isotopia Molecular Imaging Announce Successful Multi-Curie Labeling of PSMA-11 with Cyclotron Produced 68Ga Utilizing the QUANTM Irradiation SystemTM and Solid Targets Burnaby, Canada and Petach Tikva, Israel, January 19, 2021 –  ARTMS Inc. (ARTMS) and Isotopia Molecular Imaging (Isotopia) are pleased to announce the successful radiolabeling of Isotopia’s prostate cancer imaging kit product, …

Isotopia begins clinical supply collaboration with Y-mAbs Therapeutics,Inc

Isotopia begins clinical supply collaboration with Y-mAbs Therapeutics. Isotopia is pleased to announce that it has begun a collaboration with Y-mAbs Therapeutics, Inc , a late-stage clinical biopharmaceutical company for the supply of the medical radioisotope no-carrier-added Lutetium-177 (n.c.a. 177Lu) to support clinical development for 177Lu-DTPA-omburtamab for the treatment of B7-H3 positive Central Nervous System …

Isotopia Molecular Imaging and CPDC Announce Production Agreement for n.c.a. Lu-177

8 Sep 2020 Isotopia Molecular Imaging and CPDC are pleased to announce that they have entered into an agreement for the production and distribution of no-carrier-added Lutetium-177 (n.c.a. Lu-177), a critical medical radioisotope used in the manufacturing of radiopharmaceuticals for treatment of many types of cancer, including neuroendocrine tumors and prostate cancer. The Centre for …

Isotopia Molecular Imaging files Drug Master File (DMF) with the U.S. Food and FDA for Lu177 n.c.a.

Isotopia Molecular Imaging ltd. is pleased to announce that it has filed a Drug Master File (DMF) with the U.S. FDA for no-carrier-added Lutetium-177 (n.c.a. Lu177), a medical radioisotope. n.c.a. Lu177, a radiopharmaceutical precursor, is used in targeted Radionuclide therapy in the field of Precision Oncology. Radiolabeled to disease specific targeting molecules, the tumor tissue …

Isotopia Molecular Imaging and Eckert & Ziegler to start Partnership for Prostate Cancer Imaging

  Isotopia Molecular Imaging and Eckert & Ziegler to start Partnership for Prostate Cancer Imaging Petach Tikva, Israel, 10th February 2020 – Isotopia Molecular Imaging is pleased to announce that is has entered into a development partnership with Eckert & Ziegler for the development of its PSMA-11-Kit for prostate cancer imaging. Eckert & Ziegler (E&Z), …

Management

Dr. Eli Shalom CEO & Co- Founder  Linkedin An experienced radiopharmacist. Prior to founding Isotopia he was involved for eight years in the research and development and production of SPECT and PET isotopes in the National Nuclear Research Center at Nahal Soreq. With a Ph.D degree from the Hebrew University (Jerusalem) in the Synthesis of …